EPISODE · Feb 5, 2026 · 13 MIN
Eli Lilly Q4 2025 Earnings and 2026 Financial Outlook
from Daily Market Download · host Daily Market Download
Eli Lilly reported robust 2025 growth, with revenue hitting $65.2 billion. Success was driven by Mounjaro and Zepbound. Future outlook remains bullish, with 2026 revenue projected at $80–83 billion. Key focus areas include orforglipron and retatrutide for obesity and comorbidities.
What this episode covers
Eli Lilly reported robust 2025 growth, with revenue hitting $65.2 billion. Success was driven by Mounjaro and Zepbound. Future outlook remains bullish, with 2026 revenue projected at $80–83 billion. Key focus areas include orforglipron and retatrutide for obesity and comorbidities.
NOW PLAYING
Eli Lilly Q4 2025 Earnings and 2026 Financial Outlook
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m